Histamine H2 receptor antagonists are frequently used for the prevention and treatment of gastrointestinal bleeding in critically ill patients. Cimetidine iv transiently decreases mean arterial pressure (MAP) by decreasing systemic vascular resistance (SVR) in ICU patients, i-3 The mechanism of this effect is not well defined. The Ht agonists produce peripheral vasodilatation in man. 4 Cimetidine, like histamine, possesses an imidazole ring in the structure. The newer H2 antagonists, ranitidine and famotidine, do not possess imidazole tings (Figure) , and have few adverse cardiovascular effects. 2'5-7 This suggests that cimetidine might act as an agonist at HI receptors. Therefore, the effects of H t receptor blockade on the haemodynamic response to iv cimetidine were studied.
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Methods
This study was approved by the ethics committee of our institute and informed consent was obtained from the patient's next of kin. Five male and two female ICU patients, ranging in age from 35 to 83 (58.8 ---13.2 yr) were studied. The diagnoses of the patients were acute respiratory insufficiency, pulmonary infarction and COPD. All patients were haemodynamically stable and none was treated with vasopressors or inotropic agents during the study. The lungs of all patients were mechanically ventilated with continuous positive-pressure ventilation. None of the patients had catheters inserted solely for the purpose of this study, but each had a radial arterial cannula and a balloon-tipped, flow-directed thermodilution pulmonary artery catheter, Each patient was studied on two separate days. In a random fashion, they received on one day cimetidine iv and on the other a pretreatment of diphenhydriamine iv followed by cimetidine iv. Baseline haemodynamic data, including heart rate (HR), mean arterial pressure (MAP), mean pulmonary artery pressure (MPAP), pulmonary capillary wedge pressure (PCWP), central venous pressure (CVP) and cardiac output (CO), were obtained. All pressures were measured at end-expiration by calibrated transducers. Cardiac index (CI), systemic vascular resistance (SVR), and pulmonary vascular resistance (PVR) were calculated by standard formulae.
Diphenhydramine 40 mg or normal saline was given iv five minutes before the administralion of cimetidine. Cimetidine 200 mg in 20 ml saline was administered iv over two minutes. The haemodynamic variables were measured at preinjection of cimetidine and at two, four and eight minutes after the injection was completed. During the study, the ventilatory settings and fluid management were unchanged. For statistical analysis, ANOVA followed by Student's t test was used for comparison within and between the groups. P values of < 0.05 were considered significant.
Results
The results of the haemodynamic effects of cimetidine in the patients with and without diphenhydramine pretreatment are summarized in Tables I and il. Baseline haemodynamic values before cimetidine administration were comparable between the two groups.
In the non-pretreatment group, MAP decreased significantly two minutes (P < 0.01) and four minutes (P < 0.05) after cimetidine, followed by recovery to the baseline value at eight minutes. SVR also decreased significantly for the duration of the study (P < 0.01) ( Table i) .
In contrast to the non-pretreatment group, the group pretreated with diphenhydramine demonstrated only a slight or non-significant change in MAP and SVR (Table I1) .
The other haemodynamic variables did not demonstrate any significant changes in either group.
Discussion
The present study demonstrated that diphenhydramine, an HI antagonist, prevented cimetidine-induced peripheral vasodilatation followed by a reduction in MAP in critically ill patients. This suggests that cimetidine acts as an HI agonist as well as an H2 antagonist.
Other newer H2 antagonists, ranitidine and famotidine do not have the same vasodilating properties as cimetidine in critically ill patients. 2'5-7 This difference may be related to their different ring structures (Figure) . Histamine and cimetidine possess an imidazole ring, while ranitidine and famotidine possess another ring (furan and thiazole ring, respectively) in their structures. It seems that the imidazole ring activates peripheral vasodilatation mediated through the HI receptor and this may explain the lack of haemodynamic effect after ranitidine and famotidine, but not cimetidine.
Kato et al. 8 reported that the increase of peripheral blood flow by cimetidine was not influenced by diphenhydramine in anaesthetized dogs. However, there are species differences in the cardiovascular responses of histamine. 9
In conclusion, it was demonstrated that diphenhydramine prevented a reduction in MAP due to vasodilatation caused by cimetidine. We suggest that the vasodi[ating activity of cimetidine is mediated through the H~ receptor and that Hi antagonism may be useful in preventing the haemodynamic changes caused by cimetidine, especially in critically ill patients.
